[go: up one dir, main page]

JP2000508651A - 虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用 - Google Patents

虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用

Info

Publication number
JP2000508651A
JP2000508651A JP9536745A JP53674597A JP2000508651A JP 2000508651 A JP2000508651 A JP 2000508651A JP 9536745 A JP9536745 A JP 9536745A JP 53674597 A JP53674597 A JP 53674597A JP 2000508651 A JP2000508651 A JP 2000508651A
Authority
JP
Japan
Prior art keywords
osmolyte
cells
betaine
use according
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9536745A
Other languages
English (en)
Japanese (ja)
Inventor
ホイジンガー，デイーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2000508651A publication Critical patent/JP2000508651A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP9536745A 1996-04-12 1997-04-14 虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用 Pending JP2000508651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9601396A SE9601396D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 2
SE9601396-6 1996-04-12
PCT/EP1997/001861 WO1997038685A1 (fr) 1996-04-12 1997-04-14 Utilisation d'un osmolyte dans la preparation d'un medicament destine a traiter des complications resultant de l'ischemie

Publications (1)

Publication Number Publication Date
JP2000508651A true JP2000508651A (ja) 2000-07-11

Family

ID=20402175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9536745A Pending JP2000508651A (ja) 1996-04-12 1997-04-14 虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用

Country Status (7)

Country Link
EP (1) EP0946167A1 (fr)
JP (1) JP2000508651A (fr)
AU (1) AU2386097A (fr)
CA (1) CA2251071A1 (fr)
NO (1) NO984759L (fr)
SE (1) SE9601396D0 (fr)
WO (1) WO1997038685A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003063997A (ja) * 2001-06-14 2003-03-05 Otsuka Pharmaceut Co Ltd 医薬組成物
JP2009513509A (ja) * 2003-07-07 2009-04-02 ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング 肺疾患および心臓血管疾患の予防および治療用の吸入薬の製造のための極限環境細菌から得られたオスモライトの使用、ならびに活性薬剤成分としてオスモライトを含む吸入装置
JP2021147393A (ja) * 2020-03-13 2021-09-27 ロート製薬株式会社 酸化ストレス抑制剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
ATE247981T1 (de) * 1999-06-12 2003-09-15 Bitop Ag Proteinenthaltende pharmazeutische zubereitung
JP2003531833A (ja) * 2000-04-12 2003-10-28 ビトプ アクチェンゲゼルシャフト フューア ビオテヒニシェ オプティミールング フリーラジカル捕捉特性を有する物質としての適合溶質の使用
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
RU2259822C1 (ru) * 2004-02-27 2005-09-10 ЗАО "НПО ПЦ Биофизика" Противоишемическое средство, обладающее противоаритмическим и противоатерогенным действием, и способ его применения
WO2006050581A2 (fr) * 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
EP2242489A1 (fr) 2005-02-15 2010-10-27 Jallal Messadek Compositions therapeutiques combinees et leurs procedes d utilisation
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
DE102008006780A1 (de) * 2008-01-30 2009-08-06 Bitop Ag Verwendung von Tetrahydropyrimidinen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464059C (sv) * 1988-09-15 1997-06-02 Perstorp Ab Användning av inositoltrifosfat för framställning av läkemedel
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
WO1991014435A1 (fr) * 1990-03-19 1991-10-03 Brigham And Women's Hospital Traitement de troubles osmotiques a l'aide d'osmolytes organiques
US5312839A (en) * 1991-03-05 1994-05-17 Regents Of The University Of California Compounds and method for protection of cells and tissues from irreversible injury due to lactic acidosis
FR2695827B1 (fr) * 1992-09-18 1995-07-28 Pasteur Merieux Serums Vacc Solution de perfusion, de conservation et de reperfusion d'organes.
US5582839A (en) * 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003063997A (ja) * 2001-06-14 2003-03-05 Otsuka Pharmaceut Co Ltd 医薬組成物
JP2009513509A (ja) * 2003-07-07 2009-04-02 ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング 肺疾患および心臓血管疾患の予防および治療用の吸入薬の製造のための極限環境細菌から得られたオスモライトの使用、ならびに活性薬剤成分としてオスモライトを含む吸入装置
JP2021147393A (ja) * 2020-03-13 2021-09-27 ロート製薬株式会社 酸化ストレス抑制剤

Also Published As

Publication number Publication date
NO984759D0 (no) 1998-10-12
WO1997038685A1 (fr) 1997-10-23
EP0946167A1 (fr) 1999-10-06
AU2386097A (en) 1997-11-07
CA2251071A1 (fr) 1997-10-23
SE9601396D0 (sv) 1996-04-12
NO984759L (no) 1998-10-12

Similar Documents

Publication Publication Date Title
Gadau et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis
Zeng et al. Apelin protects heart against ischemia/reperfusion injury in rat
Robson et al. 11β-Hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain
Lu et al. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure
Swain et al. Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats
JP2000508651A (ja) 虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用
US5880098A (en) Therapeutic treatment
Qiu et al. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells
Wassberg et al. Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma
Shihab et al. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity
Gupta et al. Controlled curcumin release via conjugation into PBAE nanogels enhances mitochondrial protection against oxidative stress
Fudaba et al. Geranylgeranylacetone, a heat shock protein inducer, prevents primary graft nonfunction in rat liver transplantation
Abo El gheit et al. Role of serine protease inhibitor, ulinastatin, in rat model of hepatic encephalopathy: aquaporin 4 molecular targeting and therapeutic implication
Soltani et al. Oral magnesium administration prevents vascular complications in STZ-diabetic rats
Deng et al. Riluzole‐triggered GSH synthesis via activation of glutamate transporters to antagonize methylmercury‐induced oxidative stress in rat cerebral cortex
JP2000508331A (ja) 感染、炎症または免疫障害の影響を治療するためのオスモライトの使用
Nakajima et al. Attenuation of indomethacin-induced gastric mucosal injury by prophylactic administration of sake yeast-derived thioredoxin
Rossi et al. Chronic inhibition of NO synthesis per se promotes structural intimal remodeling of the rat aorta
Irie et al. Antioxidant effect of MCI-186, a new Free-Radical scavenger, on ischemia-reperfusion injury in a rat hindlimb amputation model
McCarthy et al. Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum
Poli et al. Lipid peroxidation in the reperfusion injury of the liver
Sunose et al. The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model
Song et al. Amino acid release during volume regulation by cardiac cells: cellular mechanisms
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
BE1013958A6 (fr) Antagonistes glycoproteiques.